Descovy vs. Truvada: Choosing the Right PrEP for HIV Prevention

In the ongoing fight against HIV, Pre-Exposure Prophylaxis (PrEP) has emerged as a groundbreaking and highly effective strategy for preventing HIV acquisition. PrEP involves taking a specific medication daily to reduce the risk of contracting HIV from sexual activity or injection drug use. For many years, Truvada was the sole approved medication for PrEP. However, with advancements in medical science, Descovy entered the scene, offering another option for individuals seeking to protect themselves from HIV. This comprehensive guide will delve into the nuances of Descovy and Truvada, comparing their active ingredients, efficacy, side effect profiles, approved populations, and other crucial considerations to help you and your healthcare provider make an informed decision about which PrEP regimen is right for you.

Understanding Pre-Exposure Prophylaxis (PrEP)

Pre-Exposure Prophylaxis, commonly known as PrEP, is a powerful HIV prevention tool. It involves taking a prescribed oral medication daily to significantly lower the chances of getting HIV. When taken consistently as prescribed, PrEP can reduce the risk of HIV infection from sex by about 99% and from injection drug use by at least 74%. PrEP does not protect against other sexually transmitted infections (STIs) or pregnancy, so it's often used in conjunction with other prevention methods, such as condoms.

PrEP works by interfering with HIV's ability to multiply and spread throughout the body. The medications contain antiretroviral drugs that block key enzymes HIV needs to replicate, thereby preventing the virus from establishing a permanent infection in the event of exposure.

Who Should Consider PrEP?

PrEP is recommended for individuals who are HIV-negative and at high risk of acquiring HIV. This includes:

• Sexually active adults and adolescents who have a partner with HIV (serodiscordant couples).
• Sexually active adults and adolescents who do not consistently use condoms, particularly those with multiple partners, a history of STIs, or who exchange sex for money or drugs.
• Individuals who inject drugs and share needles or other drug injection equipment.
• Anyone whose healthcare provider determines they are at substantial risk for HIV.

Before starting PrEP, it is crucial to confirm HIV-negative status through an HIV test. Taking PrEP when already HIV-positive can lead to the development of drug resistance, making future HIV treatment more challenging.

Descovy: A Newer Option for HIV Prevention

Descovy (emtricitabine 200 mg / tenofovir alafenamide 25 mg, or F/TAF) is a fixed-dose combination medication approved by the U.S. Food and Drug Administration (FDA) in 2016 for HIV treatment and in 2019 for PrEP. It combines two antiretroviral drugs: emtricitabine (FTC) and tenofovir alafenamide (TAF).

Active Ingredients and Mechanism of Action

• Emtricitabine (FTC): A nucleoside reverse transcriptase inhibitor (NRTI) that works by blocking an enzyme (reverse transcriptase) that HIV needs to make copies of itself.
• Tenofovir Alafenamide (TAF): A newer prodrug of tenofovir. TAF is designed to deliver tenofovir more efficiently to the cells where HIV replicates, leading to lower concentrations of the drug in the bloodstream compared to its predecessor, tenofovir disoproxil fumarate (TDF). This targeted delivery is intended to reduce the risk of certain side effects associated with TDF.

Both FTC and TAF are incorporated into the viral DNA chain, causing premature termination of DNA synthesis and preventing the virus from replicating effectively.

Approved Use for PrEP

Descovy is approved by the FDA for PrEP in HIV-negative adults and adolescents weighing at least 35 kg (77 lbs) who are at risk of sexually acquiring HIV, excluding individuals at risk from receptive vaginal sex. This specific approval is due to the lack of sufficient data from clinical trials involving cisgender women and individuals engaging in receptive vaginal sex.

Truvada: The Original PrEP Medication

Truvada (emtricitabine 200 mg / tenofovir disoproxil fumarate 300 mg, or F/TDF) was the first medication approved by the FDA for PrEP in 2012. It combines the same emtricitabine (FTC) with an older form of tenofovir, tenofovir disoproxil fumarate (TDF).

Active Ingredients and Mechanism of Action

• Emtricitabine (FTC): As with Descovy, FTC is an NRTI that inhibits HIV's reverse transcriptase.
• Tenofovir Disoproxil Fumarate (TDF): An older prodrug of tenofovir. TDF is absorbed into the bloodstream and then converted to its active form, tenofovir. While highly effective, TDF circulates at higher concentrations in the blood compared to TAF, which has been linked to a higher potential for certain side effects.

The mechanism of action is similar to Descovy, with both drugs working synergistically to block HIV replication.

Approved Use for PrEP

Truvada is approved by the FDA for PrEP in HIV-negative adults and adolescents weighing at least 35 kg (77 lbs) who are at risk of sexually acquiring HIV or acquiring HIV through injection drug use. This broader approval includes all sexually active individuals, regardless of the type of sexual activity (e.g., anal or vaginal sex), and individuals who inject drugs.

Descovy vs. Truvada: A Head-to-Head Comparison

While both Descovy and Truvada are highly effective PrEP medications, several key differences influence their suitability for different individuals. Understanding these distinctions is crucial for making an informed decision.

Efficacy

Both Descovy and Truvada are remarkably effective at preventing HIV when taken consistently. Clinical trials have demonstrated near-perfect efficacy when adherence is high.

• Truvada: The iPrEx study and other trials showed Truvada to be highly effective, reducing HIV risk by over 90% in people who took it consistently.
• Descovy: The DISCOVER trial compared Descovy to Truvada for PrEP in cisgender men and transgender women who have sex with men. The study concluded that Descovy was non-inferior to Truvada, meaning it was at least as effective, and in some cases, statistically superior in terms of efficacy and safety profile in the studied population.

It's important to reiterate that effectiveness hinges on strict adherence to the prescribed daily regimen. Missing doses significantly reduces protection.

Active Ingredients: TAF vs. TDF

The primary difference between Descovy and Truvada lies in the tenofovir component:

• Tenofovir Alafenamide (TAF) in Descovy: TAF is a newer prodrug that achieves high concentrations of the active tenofovir diphosphate within cells (lymphocytes) with a much lower dose compared to TDF. This means less drug circulates in the bloodstream, potentially leading to fewer systemic side effects, particularly concerning kidney and bone health.
• Tenofovir Disoproxil Fumarate (TDF) in Truvada: TDF requires a higher dose to achieve effective intracellular concentrations. This results in higher systemic exposure to tenofovir, which has been associated with a greater risk of kidney impairment and bone mineral density loss in some individuals.

Side Effects

Both medications generally have a good safety profile, but their distinct tenofovir components lead to differences in potential side effects.

Common Side Effects (for both Descovy and Truvada):

• Nausea
• Diarrhea
• Headache
• Fatigue
• Abdominal pain

These side effects are usually mild and tend to resolve within the first few weeks of starting the medication.

Specific Side Effects and Concerns:

Truvada (F/TDF):

• Kidney Function: TDF has been linked to a small but significant risk of kidney toxicity, including declines in kidney function and, in rare cases, Fanconi syndrome. Healthcare providers must monitor kidney function (creatinine clearance) before and during Truvada use.
• Bone Mineral Density (BMD): TDF can cause a small decrease in bone mineral density, particularly in the hip and spine. While this is usually not clinically significant for most people, it's a consideration for individuals with pre-existing bone conditions or risk factors for osteoporosis. BMD monitoring may be recommended for some patients.

Descovy (F/TAF):

• Kidney and Bone Health: Due to its more targeted delivery, TAF generally has a better safety profile regarding kidney and bone health compared to TDF. Clinical studies have shown less impact on kidney function and bone mineral density with Descovy. This makes Descovy a preferred option for individuals with pre-existing kidney issues or concerns about bone health.
• Lipid Levels: Some studies have indicated that Descovy may be associated with small, but statistically significant, increases in lipid levels (total cholesterol, LDL cholesterol, and triglycerides) compared to Truvada, particularly when used for HIV treatment. The clinical significance of these changes for PrEP users is still being evaluated, but it's a factor to consider for individuals with cardiovascular risk factors.
• Weight Gain: In some cohorts, particularly those using TAF-based regimens for HIV treatment, there has been an observation of modest weight gain. The extent and clinical significance of this for PrEP users are still under investigation.

Approved Populations

• Truvada: Approved for PrEP in all sexually active adults and adolescents at risk of HIV, including those engaging in receptive vaginal sex, and people who inject drugs. Its broad approval reflects extensive research across diverse populations.
• Descovy: Approved for PrEP in cisgender men and transgender women who have sex with men. It is NOT approved for PrEP in cisgender women or individuals at risk from receptive vaginal sex due to insufficient data demonstrating efficacy in these populations. This is a critical distinction that limits Descovy's applicability for certain individuals.

Cost and Availability

• Truvada: The patent for branded Truvada expired, making generic versions of F/TDF widely available. Generic Truvada is significantly more affordable, increasing access to PrEP for many individuals.
• Descovy: As a newer drug, Descovy is currently only available as a branded medication. While its cost can be higher than generic Truvada, patient assistance programs and insurance coverage can help mitigate expenses.

When to Choose Descovy vs. Truvada

The choice between Descovy and Truvada should always be made in consultation with a healthcare provider, considering an individual's specific health profile, risk factors, and lifestyle.

Consider Descovy If:

• You are a cisgender man or transgender woman who has sex with men.
• You have pre-existing kidney issues or risk factors for kidney disease.
• You have concerns about bone health, such as a history of osteoporosis or other bone conditions.
• Your healthcare provider determines that the potential benefits of Descovy's improved kidney and bone safety profile outweigh the lipid considerations.

Consider Truvada If:

• You are a cisgender woman or someone who engages in receptive vaginal sex, as Truvada is the only FDA-approved PrEP option for this route of exposure.
• You are at risk of HIV through injection drug use.
• You have no significant kidney or bone health concerns.
• You prefer a more affordable generic option.
• You have cardiovascular risk factors that might make the lipid profile changes associated with Descovy a concern.

Important Considerations Before Starting PrEP

Regardless of whether Descovy or Truvada is chosen, several essential steps and ongoing monitoring are required for safe and effective PrEP use.

1. HIV-Negative Status Confirmation

Before initiating PrEP, a healthcare provider must confirm that you are HIV-negative. This typically involves a fourth-generation HIV antigen/antibody test. If you are HIV-positive and take PrEP, it can lead to drug resistance, making future HIV treatment less effective.

2. Kidney Function Monitoring

For both medications, but especially with Truvada, baseline and ongoing monitoring of kidney function (e.g., creatinine clearance) is essential. This helps ensure the medication is safe for your kidneys and to detect any potential issues early.

3. Hepatitis B Status

Both medications contain drugs that are also active against Hepatitis B virus (HBV). If you have HBV and stop PrEP, it can lead to a severe flare-up of hepatitis. Your doctor will test for HBV before starting PrEP and monitor you accordingly.

4. Adherence Counseling

The effectiveness of PrEP relies heavily on consistent daily dosing. Your healthcare provider will discuss strategies for maintaining adherence and the importance of not missing doses.

5. Regular Follow-Up Appointments

Routine follow-up appointments, typically every three months, are necessary for:

• Repeat HIV testing to confirm ongoing HIV-negative status.
• Monitoring for side effects.
• Assessing kidney function.
• STI screening and counseling.
• Prescription refills.

6. STI Prevention

PrEP does not protect against other STIs. Consistent use of condoms and regular STI screening are still vital components of comprehensive sexual health.

Symptoms of HIV (Relevant for Pre-PrEP Screening)

It is crucial to know your HIV status before starting PrEP. If you suspect recent exposure or experience symptoms that could indicate acute HIV infection, get tested immediately and inform your doctor. Acute HIV infection symptoms, which often appear 2-4 weeks after exposure, can include:

• Fever
• Fatigue
• Swollen lymph nodes
• Sore throat
• Rash
• Muscle and joint aches
• Headache
• Nausea, vomiting, diarrhea

These symptoms are non-specific and can be mistaken for other viral illnesses, like the flu. If you experience these symptoms and have had a recent potential HIV exposure, seek medical attention immediately.

Diagnosis of HIV (Pre-PrEP Requirement)

Accurate HIV diagnosis is a prerequisite for PrEP. The primary diagnostic methods include:

• Fourth-Generation HIV-1/2 Antigen/Antibody Combination Immunoassays: These tests detect both HIV antibodies and the p24 antigen, which is present early in HIV infection. They are highly sensitive and can detect HIV sooner than antibody-only tests.
• HIV-1/2 Antibody Differentiation Immunoassays: Used to confirm positive screening tests and differentiate between HIV-1 and HIV-2.
• HIV-1 RNA Tests (Viral Load Tests): These tests directly measure the amount of HIV virus in the blood. They are used to diagnose acute infection when antibody tests may still be negative, and to monitor treatment effectiveness.

A healthcare provider will determine the appropriate testing strategy based on your exposure history and symptoms.

Prevention Beyond PrEP

While PrEP is highly effective, it is part of a broader strategy for HIV prevention. Other crucial methods include:

• Consistent and Correct Condom Use: Condoms, when used correctly and consistently, are highly effective at preventing HIV and other STIs.
• Safe Injection Practices: For individuals who inject drugs, using sterile needles and syringes for every injection and never sharing drug injection equipment can prevent HIV transmission.
• STI Testing and Treatment: Regular testing and prompt treatment of STIs can reduce the risk of HIV transmission, as some STIs can increase HIV susceptibility.
• Voluntary Medical Male Circumcision (VMMC): In regions with high HIV prevalence, VMMC has been shown to reduce the risk of HIV acquisition in men by approximately 60%.
• Treatment as Prevention (TasP): For people living with HIV, taking antiretroviral therapy (ART) as prescribed can reduce their viral load to an undetectable level. When viral load is undetectable, HIV cannot be transmitted sexually (Undetectable = Untransmittable or U=U).

When to See a Doctor

You should see a doctor for a discussion about PrEP if:

• You believe you are at high risk for HIV acquisition due to sexual activity or injection drug use.
• You are considering starting PrEP or want to switch your current PrEP medication.
• You are experiencing any new or worsening side effects while on PrEP.
• You have missed multiple doses of your PrEP medication and are concerned about your level of protection.
• You believe you may have been recently exposed to HIV and need to discuss Post-Exposure Prophylaxis (PEP) or immediate testing.
• You develop symptoms that could indicate acute HIV infection.

Frequently Asked Questions (FAQs)

Q1: Can Descovy be used for PrEP by cisgender women or for receptive vaginal sex?

A: No, Descovy is not approved by the FDA for PrEP in cisgender women or individuals at risk from receptive vaginal sex. Clinical trials did not demonstrate sufficient data for efficacy in these populations. Truvada remains the only FDA-approved PrEP option for these groups.

Q2: Is generic Truvada as effective as branded Truvada?

A: Yes, generic Truvada (emtricitabine/tenofovir disoproxil fumarate) contains the exact same active ingredients in the same dosages as branded Truvada and is considered bioequivalent. This means it works in the body in the same way and is just as effective and safe for PrEP.

Q3: Do I still need to use condoms if I'm taking PrEP?

A: While PrEP is highly effective at preventing HIV, it does not protect against other sexually transmitted infections (STIs) or pregnancy. Consistent and correct use of condoms is still recommended to reduce the risk of STIs like gonorrhea, chlamydia, syphilis, and herpes, and for contraception.

Q4: What happens if I miss a dose of PrEP?

A: The effectiveness of PrEP depends on consistent daily dosing. If you miss a dose, take it as soon as you remember, unless it's almost time for your next dose (in which case, skip the missed dose and continue with your regular schedule). Do not take two doses at once. Missing multiple doses can significantly reduce your protection against HIV. If you frequently miss doses, discuss this with your healthcare provider to explore strategies for improved adherence or alternative prevention methods.

Q5: How long does it take for PrEP to become effective?

A: The time it takes for PrEP to reach maximum protection varies depending on the type of exposure:

• For receptive anal sex: PrEP reaches maximum protection after 7 days of consistent daily use.
• For receptive vaginal sex or injection drug use: PrEP reaches maximum protection after 21 days of consistent daily use.

It's crucial to use other prevention methods, like condoms, during the initial period until PrEP has become fully effective.

Conclusion

Both Descovy and Truvada represent monumental achievements in HIV prevention, offering highly effective tools to protect individuals at risk. While both medications share the same core goal, their distinct pharmacological profiles, particularly regarding the tenofovir component, lead to important differences in their side effect profiles and approved populations. Truvada, with its longer history and broader approval, including for cisgender women and those at risk from receptive vaginal sex, remains a foundational PrEP option, now widely available as a more affordable generic. Descovy, a newer formulation, offers a generally more favorable kidney and bone safety profile, making it a compelling choice for specific populations, particularly cisgender men and transgender women who have sex with men, who may have pre-existing kidney or bone health concerns.

The decision between Descovy and Truvada is a personal one that should be made in close collaboration with your healthcare provider. They will assess your individual risk factors, health history, potential side effects, and lifestyle to recommend the most appropriate and safest PrEP regimen for you. Remember that consistent adherence to the medication schedule and regular medical follow-ups are paramount to maximizing the protective benefits of PrEP and maintaining overall sexual health.

Sources / Medical References

• Centers for Disease Control and Prevention (CDC). PrEP (Pre-Exposure Prophylaxis). Available at: https://www.cdc.gov/hiv/basics/prep/index.html
• Gilead Sciences, Inc. Descovy (emtricitabine and tenofovir alafenamide) prescribing information. Available at: https://www.gilead.com/-/media/files/pdfs/medicines/hiv/descovy/descovy_pi.pdf
• Gilead Sciences, Inc. Truvada (emtricitabine and tenofovir disoproxil fumarate) prescribing information. Available at: https://www.gilead.com/-/media/files/pdfs/medicines/hiv/truvada/truvada_pi.pdf
• Landovitz RJ, et al. Efficacy and Safety of Emtricitabine-Tenofovir Alafenamide for HIV Pre-Exposure Prophylaxis. New England Journal of Medicine. 2020;382(12):1112-1121. (DISCOVER Trial)
• Grant RM, et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. New England Journal of Medicine. 2010;363(27):2587-2599. (iPrEx Trial)
• World Health Organization (WHO). Guidelines on pre-exposure prophylaxis for HIV and post-exposure prophylaxis for HIV. Available at: https://www.who.int/publications/i/item/9789240003011